Several Chinese institutionsdistanced themselves from the doctor's claims of geneticallyediting babies, which can't be verified without an independentreview – yet that hasn't stopped investors stepping backinto bullish bets on the stocks exposed to potential success.(Photo: Getty)

|

(Bloomberg) –Gene-editing stocks traded higher after a Chineseresearcher claimed to have produced the world's first geneticallyedited babies.

|

Related: Share your DNA, get shares: Startup filesan unusual offering

|

The trio of public companies developing therapies using thetechnology known as Crispr, the method He Jiankui claimed to use inChina, outperformed peers Monday as the broader biotech marketrebounded.

|

Crispr Therapeutics AG rallied 4.5 percent, while EditasMedicine Inc. rose 3 percent and Intellia Therapeutics Inc. gained5.5 percent. Sangamo Therapeutics In., a firm that uses agene-editing platform known as Zinc finger nuclease, rose as muchas 3.4 percent.

|

Several Chinese institutions distanced themselves from He'sclaims, which can't be verified without an independent review, yetthat hasn't stopped investors stepping back into bullish bets onthe stocks exposed to potential success.

|

And the group has proved resilient to previous potentialset-backs, including studies suggesting the technique could promotecancer-causing mutations in cells and hesitance from U.S.regulators on Crispr Therapeutic's first in-human trial.

|

Crispr shares remain up close to 60 percent this year whileEditas and Intellia have fallen 6 percent and 8 percentrespectively. The Nasdaq Biotechnology Index, the broadest gaugefor the industry's performance, is off 1.8 percent this year afterthe market's recent sell-off.

|

The group's pioneer that shares the namesake of the editingtechnology has enrolled its first patient in aEuropean study and recently opened enrollment in the U.S.for patients with severe sickle cell disease in trials withpartner Vertex Pharmaceuticals Inc. Analysts and investorsare preparing for a first look at some results from the pair'searly-stage trial of their therapy in a blood disorder from theEuropean study  sometime next year.

|

The scientist is slated to speak at a session on human embryoediting at the International Summit on Human Genome Editing onWednesday in Hong Kong.

|

READ MORE:

|

The next hottest voluntary benefit — genetictesting

|

Precision medicine — worth theexpense?

|

Patients less excited about DNA tests if insurersget to see results

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.